Curcumin inhibits prosurvival pathways in chronic lymphocytic leukemia B cells and may overcome their stromal protection in combination with EGCG

Clinical Cancer Research

Volumn 15, Issue 4, 2009, Pages 1250-1258

  Ghosh, Asish K ^a   Kay, Neil E ^a   Secreto, Charla R ^a   Shanafelt, Tait D ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; CURCUMIN; EPIGALLOCATECHIN GALLATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN KINASE B; PROTEIN MCL 1; STAT3 PROTEIN; X LINKED INHIBITOR OF APOPTOSIS; ANTINEOPLASTIC AGENT; CATECHIN; DRUG DERIVATIVE; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROTEIN BCL 2; STAT3 PROTEIN, HUMAN; XIAP PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; COCULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG SENSITIVITY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; LEUKEMIA CELL; MICROENVIRONMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA; STROMA CELL; UPREGULATION; WESTERN BLOTTING; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CATECHIN; CELL SURVIVAL; CURCUMIN; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; STAT3 TRANSCRIPTION FACTOR; STROMAL CELLS; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 63149189848     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1511     Document Type: Article

References (50)

1. Keating MJ. Chronic lymphocytic leukemia [review] [65 refs]. Semin Oncol 1999;26:107-14.
2. Messmer BT, fvlessmer D, Allen SL, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005:115:755-64.
3. Reed JC. Molecular biology of chronic lymphocytic leukemia. Semin Oncol 1998;25:11-8.
4. Thomas A, El Rouby S, Reed JC, et al. Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene 1996;12: 1055-62.
5. McConkey DJ, Chandra J, Wright S, et al. Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX. J Immunol 1996; 156:2624-30.
6. Saxena A, Viswanathan S, Moshynska O. Tandon P, Sankaran K, Sheridan D. Mcl-1 and Bcl-2/Bax ratio are associated with treatment response but not with
7. Rai stage in B-cell chronic lymphocytic leukemia. Am J Hematol 2004;75:22-33.
8. Bernal A, Pastore RD, Asgary Z, et al. Survival of leukemic B cells promoted by engagement of the antigen receptor. Blood 2001;98:3050-7.
9. Frank DA, Mahajan S, Ritz J. B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. J Clin Invest 1997;100:3140-8.
10. Lee YK, Shanafelt TD, Bone ND, Strege AK, Jelinek DF, Kay NE. VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT1 and 3: implication for apoptosis resistance. Leukemia 2005;19: 513-23.
11. Lee YK, Bone ND, StregeAK, ShanafeltTD, Jelinek DF, Kay NE. VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia. Blood 2004;104: 788-94.
12. Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ. Modulation of NF-κ B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol 2000;164:2200-6.
13. Barragan M, Bellosillo B, Campas C, Colomer D, Pons G, Gil J. Involvement of protein kinase C and phosphatidylinositol 3-kinase pathways in the survival of B-cell chronic lymphocytic leukemia cells. Blood 2002;99:2969-76.
14. Ringshausen I, Schneller F, Bogner C, et al. Constitutively activated phosphatidylinositol-3 kinase (Pl- 3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cδ. Blood 2002;100: 3741-8.
15. Kay NE, Shanafelt TD, Strege AK, Lee YK, Bone ND, Raza A. Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an "angiogenic switch". Leuk Res 2007;31: 899-906.
16. Burger JA, Burger M, Kipps TJ. Chronic lymphocytic leukemia B cells express functional CXCR4 chemo-kine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood 1999;94: 3658-67.
17. Burger JA. Tsukada N, Burger M, Zvaifler NJ, DellA- quila M, KippsTJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000;96:2655-63.
18. Panayiotidis P. Jones D, Ganeshaguru K, Foroni L, Hoffbrand A. Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol 1996;92:97-103.
19. Lagneaux L, Delforge A, Bron D, De Bruyn C, Stryckmans P. Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood 1998;91:2387-96.
20. Burger JA, Zvaifler NJ, Tsukada N, Firestein GS, Kipps TJ. Fibroblast-like synoviocytes support B-cell pseudoemperipolesis via a stromal cell-derived factor-1-and CD106 (VCAM-1)-dependent mechanism. J Clin Invest 2001;107:305-15.
21. Pedersen IM, Kitada S, Leoni LM, et al. Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood 2002;100:1795-801.
22. Plate JM, Long BW, Kelkar SB. Role of [52 integrins in the prevention of apoptosis induction in chronic lymphocytic leukemia B cells. Leukemia 2000;14: 34-9.
23. de la Fuente MT, Casanova B, Garcia-Gila M, Silva A, Garcia-Pardo A. Fibronectin interaction with α4β1 integrin prevents apoptosis in B cell chronic lymphocytic leukemia: correlation with Bcl-2 and Bax. Leukemia 1999;13:266-74.
24. Buske C, Gogowski G, Schreiber K, Rave-Frank M, Hiddemann W, Wormann B. Stimulation of B-chronic lymphocytic leukemia cells by murine fibroblasts, IL-4, anti-CD40 antibodies, and the soluble CD40 ligand. Exp Hematol 1997;25:329-37.
25. Kitada S, Zapata JM, Andreeff M, Reed JC. Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br J Haematol 1999; 106:995-1004.
26. Granziero L, Ghia P. Circosta P, et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 2001;97:2777-83.
27. ShanafeltTD, Lee YK, Call TG, et al. Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies. Leuk Res2006;30:707-12.
28. ShanafeltTD, Kaufmann SH, Call TG, et al. A phase I trial of daily oral green tea extract in asymptomatic, Rai stage O-ll patients with chronic lymphocytic leukemia. Blood 2007;110:610a.
29. Aggarwal BB, Sundararn C, Malani N, Ichikawa H. Curcumin: the Indian solid gold. Adv Exp Med Biol 2007;595:1-75.
30. Aggarwal S, Ichikawa H, Takada Y, Sandur SK, Shishodia S, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of Iκ;Bα kinase and Akt activation. Mol Pharmacol 2006;69:195-206.
31. Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as "Curecumin": from kitchen to clinic. Biochem Pharmacol 2008;75:787-809.
32. Bae MK, Kim SH, Jeong JW, et al. Curcumin inhibits hypoxia-induced angiogenesis via down-regulation of HIF-1. Oncol Rep 2006;15:1557-62.
33. Lin YG, Kunnumakkara AB, Nair A, et al. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-κB pathway. Clin Cancer Res 2007;13:3423-30.
34. Everett PC, Meyers JA, Makkinje A, Rabbi M, Lerner A. Preclinical assessment of curcumin as a potential therapy for B-CLL. Am J Hematol 2007;82:23-30.
35. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990-7.
36. Roecklein BA. Torok-Storb B. Functionally distinct human marrow stromal cell lines immortalized by transduction with the human papilloma virus E6/E7 genes. Blood 1995;85:997-1005.
37. Chou TC. Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27-55.
38. Chang T, Chou T. Rational approach to the clinical protocol design for drug combinations: a review. Acta PaediatrTaiwan 2000;41:294-302.
39. Gilmore TD. The RsI/NF-κB signal transduction pathway: introduction. Oncogene 1999;18:6842-4.
40. Cuni S, Perez-Aciego P Perez-Chacon G, et al. A sustained activation of PI3K/NF-κB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia 2004;18:1391-400.
41. Kawakami H, Tomita M, Matsuda T, et al. Transcriptional activation of survivin through the NF-κB pathway by human T-cell leukemia virus type I tax. Int J Cancer 2005;115:967-74.
42. Burgering BM, Medema RH. Decisions on life and death: FOXO Forkhead transcription factors are in command when PKB/Akt is off duty. J Leukoc Biol 2003;73:689-701.
43. Ticchioni M, Essafi M, Jeandel PY, et al. Homeostatic chemokines increase survival of B-chronic lymphocytic leukemia cells through inactivation of transcription factor FOX03a. Oncogene 2007;26: 7081-91.
44. Dijkers PF, Medema RH, Lammers JW, Koenderrnan L, Coffer PJ. Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol 2000;10:1201-4.
45. Gilley J, Coffer PJ, Ham J. FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons. J Cell Biol 2003;162:613-22.
46. Chow HH, Cai Y, Hakim IA, et al. Pharmacokinetics and safety of green tea polyphenols after multiple- dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res 2003;9:3312-9.
47. Liu Q, Zhao X, Frissora F, et al. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/ lymphoma. Blood 2008;111:275-84.
48. Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001;21:2895-900.
49. Shankar S, Chen Q, Sarva K, Siddiqui I, Srivastava RK. Curcumin enhances the apoptosis-inducing potential of TRAIL in prostate cancer cells: molecular mechanisms of apoptosis, migration and angiogenesis. J Mol Signal 2007;2:10.
50. Datta SR, Brunet A, Greenberg ME. Cellularsurvival: a play in three Akts. Genes Dev1999;13:2905-27.